vs
STANDARD BIOTOOLS INC.（LAB）与Silvercrest Asset Management Group Inc.（SAMG）财务数据对比。点击上方公司名可切换其他公司
Silvercrest Asset Management Group Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.6倍（$32.0M vs $19.6M），Silvercrest Asset Management Group Inc.净利率更高（-0.4% vs -177.4%，领先177.0%），Silvercrest Asset Management Group Inc.同比增速更快（-0.0% vs -11.5%），Silvercrest Asset Management Group Inc.自由现金流更多（$15.0M vs $-23.1M），过去两年Silvercrest Asset Management Group Inc.的营收复合增速更高（2.7% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
LAB vs SAMG — 直观对比
营收规模更大
SAMG
是对方的1.6倍
$19.6M
营收增速更快
SAMG
高出11.5%
-11.5%
净利率更高
SAMG
高出177.0%
-177.4%
自由现金流更多
SAMG
多$38.1M
$-23.1M
两年增速更快
SAMG
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $32.0M |
| 净利润 | $-34.7M | $-120.0K |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -2.8% |
| 净利率 | -177.4% | -0.4% |
| 营收同比 | -11.5% | -0.0% |
| 净利润同比 | -28.8% | -107.4% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSAMG
| Q4 25 | — | $32.0M | ||
| Q3 25 | $19.6M | $31.3M | ||
| Q2 25 | $21.8M | $30.7M | ||
| Q1 25 | $40.8M | $31.4M | ||
| Q4 24 | — | $32.0M | ||
| Q3 24 | $22.1M | $30.4M | ||
| Q2 24 | $22.5M | $31.0M | ||
| Q1 24 | $45.5M | $30.3M |
净利润LABSAMG
| Q4 25 | — | $-120.0K | ||
| Q3 25 | $-34.7M | $618.0K | ||
| Q2 25 | $-33.5M | $1.9M | ||
| Q1 25 | $-26.0M | $2.5M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | $-26.9M | $2.3M | ||
| Q2 24 | $-45.7M | $2.7M | ||
| Q1 24 | $-32.2M | $3.0M |
毛利率LABSAMG
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABSAMG
| Q4 25 | — | -2.8% | ||
| Q3 25 | -168.5% | 4.3% | ||
| Q2 25 | -118.1% | 13.2% | ||
| Q1 25 | -80.8% | 15.4% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | -120.9% | 14.6% | ||
| Q2 24 | -134.5% | 17.1% | ||
| Q1 24 | -132.2% | 19.5% |
净利率LABSAMG
| Q4 25 | — | -0.4% | ||
| Q3 25 | -177.4% | 2.0% | ||
| Q2 25 | -153.7% | 6.3% | ||
| Q1 25 | -63.8% | 7.9% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | -122.0% | 7.4% | ||
| Q2 24 | -203.3% | 8.6% | ||
| Q1 24 | -70.6% | 9.9% |
每股收益（稀释后）LABSAMG
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.09 | $0.07 | ||
| Q2 25 | $-0.09 | $0.21 | ||
| Q1 25 | $-0.07 | $0.26 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | $-0.07 | $0.24 | ||
| Q2 24 | $-0.12 | $0.28 | ||
| Q1 24 | $-0.27 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $44.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $50.3M |
| 总资产 | $539.6M | $166.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSAMG
| Q4 25 | — | $44.1M | ||
| Q3 25 | $129.4M | $36.1M | ||
| Q2 25 | $158.6M | $30.0M | ||
| Q1 25 | $150.9M | $36.3M | ||
| Q4 24 | — | $68.6M | ||
| Q3 24 | $210.6M | $58.1M | ||
| Q2 24 | $269.8M | $49.9M | ||
| Q1 24 | $287.1M | $39.7M |
总债务LABSAMG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABSAMG
| Q4 25 | — | $50.3M | ||
| Q3 25 | $399.7M | $58.9M | ||
| Q2 25 | $424.5M | $64.6M | ||
| Q1 25 | $454.6M | $80.0M | ||
| Q4 24 | — | $80.7M | ||
| Q3 24 | $489.3M | $84.6M | ||
| Q2 24 | $510.3M | $85.3M | ||
| Q1 24 | $577.3M | $83.9M |
总资产LABSAMG
| Q4 25 | — | $166.6M | ||
| Q3 25 | $539.6M | $157.6M | ||
| Q2 25 | $557.0M | $152.7M | ||
| Q1 25 | $579.6M | $159.9M | ||
| Q4 24 | — | $194.4M | ||
| Q3 24 | $681.5M | $184.2M | ||
| Q2 24 | $708.7M | $177.6M | ||
| Q1 24 | $777.7M | $170.2M |
负债/权益比LABSAMG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $18.6M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $15.0M |
| 自由现金流率自由现金流/营收 | -118.1% | 46.9% |
| 资本支出强度资本支出/营收 | 4.5% | 11.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $17.0M |
8季度趋势，按日历期对齐
经营现金流LABSAMG
| Q4 25 | — | $18.6M | ||
| Q3 25 | $-22.2M | $14.6M | ||
| Q2 25 | $-20.7M | $13.8M | ||
| Q1 25 | $-30.3M | $-24.7M | ||
| Q4 24 | — | $21.6M | ||
| Q3 24 | $-27.9M | $13.3M | ||
| Q2 24 | $-39.0M | $16.0M | ||
| Q1 24 | $-62.5M | $-24.1M |
自由现金流LABSAMG
| Q4 25 | — | $15.0M | ||
| Q3 25 | $-23.1M | $13.8M | ||
| Q2 25 | $-22.6M | $13.4M | ||
| Q1 25 | $-35.3M | $-25.1M | ||
| Q4 24 | — | $19.9M | ||
| Q3 24 | $-30.1M | $12.9M | ||
| Q2 24 | $-41.0M | $15.6M | ||
| Q1 24 | $-63.3M | $-24.7M |
自由现金流率LABSAMG
| Q4 25 | — | 46.9% | ||
| Q3 25 | -118.1% | 44.1% | ||
| Q2 25 | -103.6% | 43.6% | ||
| Q1 25 | -86.6% | -80.0% | ||
| Q4 24 | — | 62.2% | ||
| Q3 24 | -136.4% | 42.4% | ||
| Q2 24 | -182.2% | 50.4% | ||
| Q1 24 | -138.9% | -81.6% |
资本支出强度LABSAMG
| Q4 25 | — | 11.4% | ||
| Q3 25 | 4.5% | 2.6% | ||
| Q2 25 | 8.7% | 1.5% | ||
| Q1 25 | 12.4% | 1.3% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | 10.2% | 1.2% | ||
| Q2 24 | 8.6% | 1.1% | ||
| Q1 24 | 1.7% | 2.0% |
现金转化率LABSAMG
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | — | -10.01× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | — | -8.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
